Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Nektar Therapeutics (NKTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,617,231
  • Shares Outstanding, K 173,090
  • Annual Sales, $ 307,710 K
  • Annual Income, $ -96,690 K
  • 36-Month Beta 2.91
  • Price/Sales 215.24
  • Price/Cash Flow N/A
  • Price/Book 3.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.70
  • Number of Estimates 6
  • High Estimate -0.61
  • Low Estimate -0.80
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -400.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.50 +13.46%
on 11/09/18
48.44 -21.53%
on 10/22/18
-10.18 (-21.12%)
since 10/19/18
3-Month
33.50 +13.46%
on 11/09/18
69.76 -45.51%
on 09/05/18
-22.02 (-36.68%)
since 08/17/18
52-Week
33.50 +13.46%
on 11/09/18
111.36 -65.87%
on 03/12/18
-6.98 (-15.51%)
since 11/17/17

Most Recent Stories

More News
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of JT, NKTR, SYF and SONS

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

SYF : 25.53 (-1.47%)
SONS : 7.83 (+2.76%)
JT : 5.45 (-3.54%)
NKTR : 38.01 (-0.58%)
INVESTOR ALERT NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations...

NKTR : 38.01 (-0.58%)
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Nektar Therapeutics Investors

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") investors that a securities fraud class action lawsuit has been filed in the United States District...

NKTR : 38.01 (-0.58%)
SHAREHOLDER ALERT: TGTX ABBV MGTI HAS CPB CHGG ADNT GOOG NKTR SYF RBBN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

TGTX : 5.16 (-3.55%)
GOOG : 1,020.00 (-3.91%)
SYF : 25.53 (-1.47%)
CPB : 38.45 (-0.52%)
ADNT : 24.11 (+0.63%)
SONS : 7.83 (+2.76%)
CHGG : 24.79 (-5.88%)
ABBV : 89.48 (-2.24%)
MGTI : 0.0920 (-16.36%)
HAS : 94.89 (-2.89%)
NKTR : 38.01 (-0.58%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR

Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics, Inc. ("Nektar" or the "Company") (NASDAQ: NKTR) and certain of its officers. The class action, filed in...

NKTR : 38.01 (-0.58%)
CLASS ACTION UPDATE for TRVN, NKTR and SYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...

TRVN : 0.60 (-6.25%)
SYF : 25.53 (-1.47%)
NKTR : 38.01 (-0.58%)
Pawar Law Group Announces a Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Nektar Therapeutics (NASDAQ: NKTR)...

NKTR : 38.01 (-0.58%)
Nektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs

Nektar Therapeutics (Nasdaq: NKTR) today announced the appointment of Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs. In this role, Dr. Lin will...

NKTR : 38.01 (-0.58%)
40.6% Return Seen to Date on SmarTrend Nektar Therapeut Call (NKTR)

SmarTrend identified a Downtrend for Nektar Therapeut (NASDAQ:NKTR) on September 13th, 2018 at $62.24. In approximately 2 months, Nektar Therapeut has returned 40.60% as of today's recent price of $36.97....

NKTR : 38.01 (-0.58%)
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APOG, JT, COST, CWH, OZK, NKTR and AQUA

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

OZK : 26.73 (+1.02%)
COST : 228.74 (-0.99%)
AQUA : 8.56 (-0.81%)
CWH : 17.00 (+0.53%)
APOG : 35.63 (-1.60%)
JT : 5.45 (-3.54%)
NKTR : 38.01 (-0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade NKTR with:

Business Summary

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists...

See More

Key Turning Points

2nd Resistance Point 39.87
1st Resistance Point 38.94
Last Price 38.01
1st Support Level 36.71
2nd Support Level 35.41

See More

52-Week High 111.36
Fibonacci 61.8% 81.62
Fibonacci 50% 72.43
Fibonacci 38.2% 63.24
Last Price 38.01
52-Week Low 33.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar